609.F ABIONYX PHARMA SA EO-05
- Market cap
- EUR 69.5M
- P/E
- -
- P/B
- 4.26x
- ROE
- -123.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 609.F undervalued?
Graham numberThe Graham number of ABIONYX PHARMA SA EO-05 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ABIONYX PHARMA SA EO-05 fundamental analysis
No fundamental analysis for ABIONYX PHARMA SA EO-05 yet.
ABIONYX PHARMA SA EO-05 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ABIONYX PHARMA SA EO-05
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase …
Full company profileABIONYX PHARMA SA EO-05 financial statements
ABIONYX PHARMA SA EO-05 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 675K | 5.25M | 4.64M | 4.55M | 4.06M |
| Gross Profit | 259K | 636K | 618K | 844K | 534K |
| Operating Income | -5.87M | -3.98M | -3.17M | -4.32M | -5.43M |
| EBITDA | - | -4.01M | -3.35M | -4.21M | -5.30M |
| Net Income | -5.82M | -4.21M | -3.52M | -4.38M | -5.55M |
| EPS | -0.21 | -0.15 | -0.11 | -0.13 | -0.16 |
| Balance Sheet | |||||
| Total Assets | 21.8M | 15.8M | 14.8M | 13.5M | 13.1M |
| Total Liabilities | 11.2M | 8.65M | 6.91M | 6.03M | 8.60M |
| Shareholders' Equity | 10.7M | 7.17M | 7.92M | 7.52M | 4.51M |
| Cash & Short-term Investments | 7.94M | 4.05M | 4.10M | 3.24M | 3.52M |
| Cash Flow | |||||
| Operating Cash Flow | -6.69M | -3.36M | -3.70M | -3.63M | -2.93M |
| Capital Expenditure | 166K | 175K | 130K | 76.0K | 242K |
| Free Cash Flow | -6.86M | -3.53M | -3.83M | -3.71M | -3.18M |
| Ratios | |||||
| ROE | -54.5% | -58.7% | -44.4% | -58.3% | -123.0% |
| ROA | -26.7% | -26.6% | -23.7% | -32.4% | -42.3% |
| Net Profit Margin | -862.5% | -80.1% | -75.8% | -96.3% | -136.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ABIONYX PHARMA SA EO-05 dividends
ABIONYX PHARMA SA EO-05 has not paid dividends in the last 5 fiscal years.
Who owns ABIONYX PHARMA SA EO-05
- Insiders 28.95%
- Institutions 3.61%
- Public & others 67.44%
- Shares outstanding 43.8M
- Free float 22.7M
ABIONYX PHARMA SA EO-05 company profile
- Company name
- ABIONYX PHARMA SA EO-05
- Ticker
- 609.F
- ISIN
- FR0012616852
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 49
- Fiscal year end
- December
- Address
- Building D2, Balma, France, 31130
- Phone
- 33 5 62 24 97 06
- Website
- abionyx.com
About ABIONYX PHARMA SA EO-05
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. ABIONYX Pharma SA has a strategic partnership with Lille University Hospital"burn treatment center and intensive care unit to explore the potential of CER-001 in severe burn patients at high risk for sepsis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France.
ABIONYX PHARMA SA EO-05 management
5- Sir Cyrille Tupin CPACEO, GM & Director · born 1977
- Prof. Christian Chavy MBAIndependent Director · born 1950
- Mr. Emmanuel De FougerouxAdministrative & Financial Director
- Ms. Constance Keyserling Peyrottes M.S.Vice President of Clinical, Regulatory Development & Operations · born 1961
- Mr. Laurent GuerciChief Digital & Innovation Officer